SLC5A2 and type 1 diabetes mellitus: In clinical studies, SGLT2 inhibitors demonstrate noticeably advantageous effects in T1DM, including lowering HbA1c and glucose variability, increasing time in optimal glucose range, as well as reduction in weight and insulin dose with little risk of hypoglycemia [77].